Zhejiang Conba Pharmaceutical Co (SHSE:600572) Accounts Payable & Accrued Expense : ¥2,349 Mil (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Zhejiang Conba Pharmaceutical Co Accounts Payable & Accrued Expense?

Zhejiang Conba Pharmaceutical Co's quarterly accounts payable & accrued expense increased from Sep. 2023 (¥2,180 Mil) to Dec. 2023 (¥2,192 Mil) and increased from Dec. 2023 (¥2,192 Mil) to Mar. 2024 (¥2,349 Mil).

Zhejiang Conba Pharmaceutical Co's annual accounts payable & accrued expense increased from Dec. 2021 (¥1,648 Mil) to Dec. 2022 (¥1,800 Mil) and increased from Dec. 2022 (¥1,800 Mil) to Dec. 2023 (¥2,192 Mil).

Zhejiang Conba Pharmaceutical Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Zhejiang Conba Pharmaceutical Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Conba Pharmaceutical Co Accounts Payable & Accrued Expense Chart

Zhejiang Conba Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

1,549.63

1,348.32

1,648.38

1,800.34

2,192.01

Zhejiang Conba Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															2,021.92	2,116.12	2,179.86	2,192.01	2,348.76

Zhejiang Conba Pharmaceutical Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Zhejiang Conba Pharmaceutical Co (SHSE:600572) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Conba Pharmaceutical Co Ltd (SHSE:600572) » Definitions » Accounts Payable & Accrued Expense

Traded in Other Exchanges

N/A

Address

No. 568 Binkang Road, New and High-Technology Development Zone, Binjiang District, Zhejiang, Hangzhou, CHN, 310052

Website

http://www.conba.com.cn

Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.

Executives

Hu Ji Qiang	Director
Yuan Zhen Xian	senior management
Yin Shi Shui	Supervisors
Xu Chun Ling	senior management
Jin Zu Cheng	Directors, senior managers
Ye Jian Feng	Supervisors
Ying Chun Xiao	Director
Chen Ming	Director
Luo Guo Liang	Director
Wu Zhong Shi	Supervisors
Wang Ru Wei	Director
Yang Jun De	senior management
Yang Xian Min	senior management
Chen Yue Zhong	senior management
Li Jian Zhong	Supervisors

Zhejiang Conba Pharmaceutical Co (SHSE:600572) Headlines

No Headlines